Group L.P.Crg Partners Iii ... Net Worth

The estimated Net Worth of Group L.P.Crg Partners Iii ... is at least $4.37 Million dollars as of 23 December 2020. Group Iii owns over 8,767,185 units of Assertio stock worth over $254,000 and over the last 4 years Group sold ASRT stock worth over $4,118,858.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Group Iii ASRT stock SEC Form 4 insiders trading

Group has made over 2 trades of the Assertio stock since 2020, according to the Form 4 filled with the SEC. Most recently Group sold 8,767,185 units of ASRT stock worth $3,243,858 on 23 December 2020.

The largest trade Group's ever made was selling 8,767,185 units of Assertio stock on 23 December 2020 worth over $3,243,858. On average, Group trades about 5,633,593 units every 3 days since 2020. As of 23 December 2020 Group still owns at least 200,000 units of Assertio stock.

You can see the complete history of Group Iii stock trades at the bottom of the page.

Insiders trading at Assertio

Over the last 4 years, insiders at Assertio have traded over $6,616,337 worth of Assertio stock and bought 68,828 units worth $87,071 . The most active insiders traders include Group L.P.Crg Partners Iii ..., Timothy P Walbert, and Daniel A. Peisert. On average, Assertio executives and independent directors trade stock every 21 days with the average trade being worth of $278,566. The most recent stock trade was executed by Jeff L Vacirca on 11 June 2024, trading 10,000 units of ASRT stock currently worth $11,100.

What does Assertio do?

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Complete history of Group Iii stock trades at Assertio

Assertio executives and stock owners

Assertio executives and other stock owners filed with the SEC include:

• Daniel A. Peisert,
  Pres, CEO & Director
• Jeff Christensen,
  Sr. VP of Commercial
• Sam Schlessinger,
  Sr. VP & Gen. Counsel
• Max Nemmers,
  Head of Investor Relations & Admin.
• Dr. Jack Hoblitzell Ph.D.,
  Sr. VP of Technical Operations
• Ajay Patel,
  Sr. VP & Chief Accounting Officer
• Bill Iskos,
  Sr. VP of Operations
• Paul Schwichtenberg,
  Sr. VP & CFO
• Sigurd Kirk,
  Director
• Ajay Patel,
  SVP and CFO
• Paul Schwichtenberg,
  SVP, CCO
• Jeff L Vacirca,
  Director
• Peter D Staple,
  Director
• Mark Strobeck,
  EVP & Chief Operating Officer
• Todd N Smith,
  Director, Pres & CEO
• James L Tyree,
  Director
• Timothy P Walbert,
  Director
• Megan C. Timmins,
  SVP, Gen Csl & Sec
• Arthur J Higgins,
  Director
• William Mckee,
  Director
• David E. Wheadon,
  Director
• Group L.P.Crg Partners Iii ...,
  
• Sam Schlessinger,
  SVP, General Counsel
• Sravan Kumar Emany,
  Director
• Daniel A. Peisert,
  President & CEO
• Heather L Mason,
  Interim Executive Officer
• Brendan P. O'grady,
  CEO